Literature DB >> 11851583

beta-Blockers in heart failure: clinical applications.

Michael H Farrell1, JoAnne Micale Foody, Harlan M Krumholz.   

Abstract

beta-Blockers reduce morbidity and mortality in heart failure patients with left ventricular systolic dysfunction and stable fluid status. The successful adoption of beta-blocker guidelines for these patients requires an understanding of the value of this therapy and effective systems to maintain safety and ensure high quality of care. This article distills scientific evidence and consensus guidelines into a series of cases and practical answers about patient selection, discussions with patients, management and monitoring, and systems improvements to optimize quality of care, safety, and benefit for all patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11851583     DOI: 10.1001/jama.287.7.890

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications.

Authors:  M Weiner; T E Stump; C M Callahan; J N Lewis; C J McDonald
Journal:  Qual Saf Health Care       Date:  2005-04

2.  Mechanism of carvedilol induced action potential and calcium alternans.

Authors:  Elizabeth Martinez-Hernandez; Giedrius Kanaporis; Lothar A Blatter
Journal:  Channels (Austin)       Date:  2022-12       Impact factor: 3.493

3.  Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft.

Authors:  Mustafa Aldemir; İbrahim Keleş; Mustafa Karalar; Evren Tecer; Fahri Adalı; Mehmet Bilgehan Pektaş; Ali İhsan Parlar; Osman Tansel Darçın
Journal:  Anatol J Cardiol       Date:  2015-02-11       Impact factor: 1.596

Review 4.  Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure.

Authors:  Liza Grosman-Rimon; Filio Billia; Evan Wright; Shemy Carasso; Gabby Elbaz-Greener; Erez Kachel; Vivek Rao; David Cherney
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.